Gaurav Bissa, V-P Technicals & Derivatives, , said there can be some more upside in the pharma names. But yes, one has to be selective because there are certain names which are still looking weak, like Dr Reddys,” says he. Excerpts from an interview:This…

Click here to view the original article.